RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 27, 2026, and May 28, 2026. The filing details the results of the Company's 2026 Annual Meeting of Stockholders and the subsequent filing of a Certificate of Amendment to its Articles of Incorporation with the State of Nevada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance.
Material Changes and Voting Results
- Authorized Share Increase: Stockholders approved an amendment to increase authorized common stock from 150,000,000 to 200,000,000 shares. The amendment was filed on May 28, 2026.
- Equity Plan Amendment: Stockholders approved an increase of 3,000,000 shares available for issuance under the 2021 Equity Incentive Plan, bringing the total to 18,052,942 shares.
- Director Elections:
- Charles J. Casamento: Elected as a Class II Director. Received 33,859,106 votes "For" and 20,888,478 votes "Withheld".
- Sergio Traversa: Elected as a Class II Director. Received 54,124,764 votes "For" and 622,820 votes "Withheld".
- Continuing Directors: Fabiana Fedeli (Class I), Paul Kelly (Class III), and John Glasspool (Class III) remain on the board.
- Auditor Ratification: Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future operations, or new risk factors. The document references the 2026 Proxy Statement for further details on the Charter Amendment and Equity Plan.
Investor Verification Checklist
- Verify the impact of the 50,000,000 share increase in authorized capital on potential future dilution.
- Review the 2026 Proxy Statement (filed April 17, 2026) for detailed terms of the 2021 Equity Incentive Plan amendment.
- Confirm the specific terms of the Class II director terms (36 months) and their alignment with the Company's staggered board structure.
- Check subsequent filings for any immediate issuances of shares under the newly expanded equity plan.